Contact
searchSearch
HMP Global
Quiz

Treat-to-Target vs Symptom-Based Gout Care: What’s the Difference?

Riya Gandhi, MA
04/01/2026
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Rheumatology & Arthritis Learning Network or HMP Global, its employees, and affiliates.

Related Content

Quiz
Why Flare Frequency Matters in Clinical Trials
04/01/2026
Riya Gandhi, MA
Explore why gout flare frequency remains a key primary outcome in clinical trials despite the disease’s chronic and erosive nature. This quiz reinforces outcome selection and trial design principles in gout research.
Explore why gout flare frequency remains a key primary outcome in clinical trials despite the disease’s chronic and erosive nature. This quiz reinforces outcome selection and trial design principles in gout research.
Explore why gout flare frequency...
04/01/2026
Rheumatology & Arthritis
Quiz
Hyperuricemia vs Gout: Understanding the Clinical Relationship
04/01/2026
Riya Gandhi, MA
Test your knowledge of the relationship between hyperuricemia and clinical gout. This quiz clarifies key distinctions that impact diagnosis, risk assessment, and treatment decisions in rheumatology practice.
Test your knowledge of the relationship between hyperuricemia and clinical gout. This quiz clarifies key distinctions that impact diagnosis, risk assessment, and treatment decisions in rheumatology practice.
Test your knowledge of the...
04/01/2026
Rheumatology & Arthritis
Quiz
Pegloticase + Methotrexate: What Rising Uric Acid Means
04/01/2026
Riya Gandhi, MA
Assess your understanding of pegloticase therapy by interpreting rising serum urate levels in combination treatment protocols. This quiz highlights key monitoring principles and response criteria from the AGILE trial.
Assess your understanding of pegloticase therapy by interpreting rising serum urate levels in combination treatment protocols. This quiz highlights key monitoring principles and response criteria from the AGILE trial.
Assess your understanding of...
04/01/2026
Rheumatology & Arthritis
Clinical Trials
Shorter Pegloticase Infusions Maintain Safety and Efficacy in Uncontrolled Gout
03/18/2026
Jessica Garlewicz
For practicing rheumatologists, the key takeaway is that a 60-minute infusion may offer a more practical option without compromising outcomes.
For practicing rheumatologists, the key takeaway is that a 60-minute infusion may offer a more practical option without compromising outcomes.
For practicing rheumatologists,...
03/18/2026
Rheumatology & Arthritis

Popular Articles

News
Ultraprocessed Food Intake and SLE Incidence Among Women
07/12/2024
Jessica Garlewicz
Sugar- and artificially sweetened-beverages were among the key contributors to heightened risk of developing systemic lupus erythematosus.
Sugar- and artificially sweetened-beverages were among the key contributors to heightened risk of developing systemic lupus erythematosus.
Sugar- and artificially...
07/12/2024
Rheumatology & Arthritis
News
Subcutaneous Ustekinumab Cost Rose 84% Under Medicare Part D, Set to Drop Under Negotiated Price Reduction
08/15/2024
Rebecca Mashaw
Coverage changes omitted self-injected therapies from Part B, but new negotiated price will reduce costs 66-67%.
Coverage changes omitted self-injected therapies from Part B, but new negotiated price will reduce costs 66-67%.
Coverage changes omitted...
08/15/2024
Rheumatology & Arthritis
Sponsored Video
The RheuMuseum Lecture Series: The Pathogenesis of Psoriatic Arthritis
06/04/2024
The RheuMuseum Lecture Series continues with Professor Iain McInnes taking a deeper dive into the pathogenesis of psoriatic arthritis.
The RheuMuseum Lecture Series continues with Professor Iain McInnes taking a deeper dive into the pathogenesis of psoriatic arthritis.
The RheuMuseum Lecture Series...
06/04/2024
Rheumatology & Arthritis
FDA Alert
FDA Approves Bimekizumab for PsA, nr-axSpA and AS
09/23/2024
Rebecca Mashaw
Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Already approved for plaque...
09/23/2024
Rheumatology & Arthritis
News
Predictors of Demyelinating Disease in axSpA
07/11/2024
Jessica Garlewicz
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
Key predictors of demyelinating...
07/11/2024
Rheumatology & Arthritis

Partner Spotlight

Axial Involvement in SpA: A Patient-Centered Exploration, Chapter 1
SPONSORED
Axial Involvement in SpA, Chapter 1
04/26/2022
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses...
04/26/2022
Rheumatology & Arthritis

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use